Novo Nordisk signs up to $1.3B deal with Nanexa; Swedish firm jumps 100%

Novo Nordisk has entered a partnership worth up to US$1.3 billion with Swedish drug delivery firm Nanexa, leveraging its PharmaShell technology for controlled-release formulations. Nanexa's shares surged 100% in Stockholm on the news. The deal underscores Novo Nordisk's investment in advanced drug delivery, though financial terms and development milestones remain undisclosed.